ADMA logo

ADMA Biologics Inc (ADMA)

$9.11

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ADMA

Market cap

$2.04B

EPS

0.7

P/E ratio

13

Price to sales

3.98

Dividend yield

--

Beta

0.774757

Price on ADMA

Previous close

$8.95

Today's open

$8.92

Day's range

$8.81 - $9.13

52 week range

$7.21 - $20.46

Profile about ADMA

CEO

Adam S. Grossman

Employees

647

Headquarters

Ramsey, NJ

Exchange

NASDAQ Global Market

Shares outstanding

223984680

Issue type

Common Stock

ADMA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ADMA

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.

news source

Zacks Investment Research • Sep 18, 2026

news preview

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)

Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.

news source

Newsfile Corp • Sep 14, 2026

news preview

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.

news source

Zacks Investment Research • Sep 11, 2026

news preview

Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know

Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the prior day.

news source

Zacks Investment Research • Sep 10, 2026

news preview

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company").

news source

PRNewsWire • Sep 8, 2026

news preview

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

news source

Zacks Investment Research • Sep 8, 2026

news preview

Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?

news source

Zacks Investment Research • Sep 4, 2026

news preview

ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

news source

Newsfile Corp • Aug 26, 2026

news preview

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

news source

PRNewsWire • Aug 21, 2026

news preview

ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

news source

PRNewsWire • Aug 21, 2026

news preview

¹ Disclosures

Get started with M1

Invest in ADMA Biologics Inc

Open an M1 investment account to buy and sell ADMA Biologics Inc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ADMA on M1